603259:SHA
WuXi AppTec Co Ltd
CN¥154.29
arrow_upward
+0.07%(+0.11) 1H
15 Okt, 2:53:10 PTG GMT+8 · CNY
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 603259...
Buka
CN¥152.00
Tinggi
CN¥156.70
Rendah
CN¥151.82
Permodalan Pasaran
484.94B
Purata volum
34.07J
Volum
31.53J
Dividen
1.35%
Dividen suku tahunan
CN¥0.52
Tarikh tanpa dividen
4 Sep 2026
Nisbah H/P
20.99
tgi 52 mgu
CN¥173.60
rdh 52 mgu
CN¥87.09
EPS
CN¥7.35
Syer tertunggak
1.05B
Bilangan pekerja
36K
Buka
CN¥152.00
Tinggi
CN¥156.70
Rendah
CN¥151.82
Permodalan Pasaran
484.94B
Purata volum
34.07J
Volum
31.53J
Dividen
1.35%
Dividen suku tahunan
CN¥0.52
Tarikh tanpa dividen
4 Sep 2026
Nisbah H/P
20.99
tgi 52 mgu
CN¥173.60
rdh 52 mgu
CN¥87.09
EPS
CN¥7.35
Syer tertunggak
1.05B
Bilangan pekerja
36K
Cerita berita
Daripada sumber web dan rakan kongsi berita
ad-hoc-news.de
·
17 jam lalu
Morgan Stanley keeps HKD 207.40 target for WuXi AppTec stock
ad-hoc-news.de
·
22 jam lalu
Huaxi Securities maintains Buy for WuXi AppTec stock
ad-hoc-news.de
·
1 hari lalu
WuXi AppTec stock pre-market at EUR 23.18
ad-hoc-news.de
·
1 hari lalu
WuXi AppTec sets October 27 results date while WuXi AppTec stock costs EUR 23.60
Profil
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
Perihal WuXi AppTec Co Ltd